Optonol

Company Overview

Snapshot

Founded in January 1996 by Yaron Ira and Benad Goldwasser, Optonol operated with 1–10 employees. The company raised $30 million across 2 funding rounds from 5 investors before being acquired by Alcon in December 2009.

Business overview

Optonol specializes in developing miniature surgical implants designed to lower intra-ocular pressure in patients suffering from glaucoma. The company's core product, Ex-Press, is a key offering in the medical devices sector, serving the healthcare industry with solutions for medical treatment and therapeutics.

Company Intelligence Q&A

What is Optonol's flagship product?

Optonol's flagship product is Ex-Press, a miniature surgical implant used to lower intra-ocular pressure in patients with glaucoma.

When was Optonol acquired and by whom?

Optonol was acquired by Alcon in December 2009. Following this, Alcon was acquired by Novartis a year later.

What was the initial cash payment for Optonol's acquisition?

In December 2009, Alcon provided an initial cash payment of $150 million for Optonol's Ex-Press mini-glaucoma shunt family of products.

Which investors participated in Optonol's April 2006 funding round?

In April 2006, Optonol received funding from investors including Israel HealthCare Ventures.

Which investors participated in Optonol's March 2000 funding round?

In March 2000, Optonol received funding from investors including Avi Fischer.